Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ANGO
ANGO logo

ANGO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
10.910
Open
10.790
VWAP
10.76
Vol
332.41K
Mkt Cap
445.83M
Low
10.645
Amount
3.58M
EV/EBITDA(TTM)
155.20
Total Shares
41.32M
EV
413.92M
EV/OCF(TTM)
93.06
P/S(TTM)
1.42
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.
Show More

Events Timeline

(ET)
2026-04-02
16:40:00
Major U.S. Averages Mixed as Oil Prices Rise to $111.54
select
2026-04-02
12:30:00
Major Averages Decline as Oil Prices Rise
select
2026-04-02
06:10:00
FY26 EPS Consensus at 29c, Revenue View Raised to $313.5M-$315.5M
select
2026-04-02
06:10:00
Company Reports Q3 Revenue of $78.4M, Beating Expectations
select
2026-01-06 (ET)
2026-01-06
16:30:00
Dow Jones Rises 484.90 Points to Close at 49,462.08
select
2026-01-06
12:20:00
Dow Jones Index Rises 331.23 Points to 49,308.41
select
2026-01-06
06:30:00
AngioDynamics Ends FY 2026 Q2 with $41.6M in Cash
select
2026-01-06
06:10:00
Jim Clemmer Announces Retirement Plans for Fiscal 2027
select

News

Yahoo Finance
9.5
04-02Yahoo Finance
AngioDynamics Reports Strong Revenue Growth in Med Tech Segment
  • Significant Revenue Growth: AngioDynamics reported an 8.9% increase in total revenue to $78.4 million, with the Med Tech segment achieving $37.3 million in revenue, reflecting a robust 19% growth that underscores the company's strong performance and rising market demand.
  • Auryon Platform's Continued Strength: The Auryon platform achieved its 19th consecutive quarter of double-digit year-over-year growth, generating $16.3 million in revenue, indicating its competitive position and technological superiority, which are expected to further drive the company's future growth.
  • Optimistic Financial Outlook: The company raised its full-year revenue guidance to $313.5 million to $315.5 million, while also increasing adjusted EBITDA guidance to $10 million to $12 million, reflecting management's confidence in future performance.
  • Gross Margin Decline Challenges: Despite revenue growth, gross margin decreased by 110 basis points year-over-year, primarily due to tariffs and inflation, with tariff expenses expected to range between $4 million and $6 million for fiscal year 2026, potentially impacting the company's profitability.
seekingalpha
9.5
04-02seekingalpha
AngioDynamics Reports Strong Q3 FY2026 Earnings Growth
  • Significant Revenue Growth: AngioDynamics reported Q3 revenue of $78.4 million, an 8.9% increase year-over-year, surpassing analyst estimates of $76.766 million, which enhances market confidence in the company's performance.
  • Strong Med Tech Performance: The Med Tech segment generated $37.3 million in revenue, up 19% and accounting for 48% of total revenue, reflecting a continued shift in business mix that is expected to drive future profitability and market share growth.
  • Auryon Momentum: Auryon achieved its 19th consecutive quarter of double-digit year-over-year growth, supported by expansion into the hospital market and CE Mark approval, indicating strengthening competitive positioning in the medical device sector.
  • Optimistic Outlook: The company raised its FY2026 net sales guidance to $313.5 million to $315.5 million and adjusted EBITDA guidance to $10 million to $12 million, demonstrating management's confidence in future performance and positive market expectations.
NASDAQ.COM
9.5
04-02NASDAQ.COM
AngioDynamics Reports Wider Loss in Q3 Earnings
  • Loss Report: AngioDynamics reported a GAAP net loss of $8.1 million in Q3, translating to a loss per share of $0.19, which is a significant increase from last year's loss of $4.4 million or $0.11 per share, indicating worsening financial health.
  • Adjusted Financials: On a pro forma basis, the net loss was $13.1 million or $0.31 per share, compared to a loss of $9.9 million or $0.24 per share last year, reflecting ongoing operational challenges faced by the company.
  • Sales Growth: The company achieved net sales of $78.4 million in Q3, an 8.9% increase year-over-year, with Med Tech sales rising to $37.3 million, a 19.0% increase from $31.3 million last year, demonstrating strong market demand.
  • Revised Outlook: For fiscal 2026, the adjusted loss per share is now expected to be in the range of $0.30 to $0.23, revised from a previous guidance of $0.33 to $0.23, while adjusted EBITDA expectations have been raised to $10.0 to $12.0 million, indicating cautious optimism about future performance.
Newsfilter
9.5
04-02Newsfilter
AngioDynamics Reports Sixth Consecutive Quarter of Double-Digit Growth
  • Performance Highlights: AngioDynamics reported net sales of $78.4 million for Q3 FY 2026, an 8.9% year-over-year increase, with the Med Tech segment achieving $37.3 million in sales, reflecting a robust 19.0% growth that underscores the company's strong position in the medical technology sector.
  • Adjusted EBITDA: The company recorded an adjusted EBITDA of $1.8 million in Q3, up 38.5% from $1.3 million in the prior year, indicating ongoing improvements in operational efficiency and cost management, which bolster confidence in future profitability.
  • Cash Flow Status: As of February 28, 2026, AngioDynamics maintained a cash balance of $37.8 million and a debt-free status, demonstrating strong financial management and providing ample resources for future investments and expansion.
  • Future Outlook: The company raised its guidance for FY 2026, now expecting net sales between $313.5 million and $315.5 million and adjusted EBITDA of $10 million to $12 million, reflecting management's confidence in sustained growth moving forward.
seekingalpha
9.5
04-02seekingalpha
AngioDynamics Q3 Earnings Exceed Expectations
  • Earnings Beat: AngioDynamics reported a Q3 non-GAAP EPS of -$0.07, beating expectations by $0.04, indicating improved profitability and boosting market confidence in future performance.
  • Revenue Growth: The company achieved revenue of $78.42 million in Q3, an 8.9% year-over-year increase that surpassed market expectations by $1.65 million, demonstrating strong demand for its products, particularly in the Med Tech sector.
  • Strong Med Tech Sales: Med Tech net sales reached $37.3 million, a 19% increase from $31.3 million in the prior-year period, showcasing significant growth in market share and competitiveness in this segment.
  • Guidance Upgrade for FY 2026: AngioDynamics raised its FY 2026 net sales guidance to $314 million, up from the previous range of $312 million to $314 million, reflecting a positive outlook for future growth.
seekingalpha
9.5
04-01seekingalpha
Major Earnings Expected Before Thursday Bell
  • Earnings Preview: Major earnings reports expected on Thursday include Acuity (AYI), Lindsay Corporation (LNN), and AngioDynamics (ANGO), all of which hold significant positions in their respective industries, and their results will impact market sentiment.
  • Investor Focus: Investors will closely monitor these earnings to assess company performance and future outlook, particularly in the current economic climate where corporate profitability and growth potential are under scrutiny.
  • Industry Impact: As a leader in the lighting sector, Acuity's earnings will signal trends in construction and infrastructure investment, while the performance of Lindsay and AngioDynamics may influence investor confidence in the agriculture and medical device sectors.
  • Earnings Season: As the earnings season progresses, market expectations and reactions to company performances will directly affect stock market volatility, prompting investors to pay attention to upcoming reports to adjust their investment strategies.
Wall Street analysts forecast ANGO stock price to rise
3 Analyst Rating
Wall Street analysts forecast ANGO stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
16.00
Averages
19.33
High
24.00
Current: 0.000
sliders
Low
16.00
Averages
19.33
High
24.00
Freedom Broker
Buy
initiated
$16
AI Analysis
2026-04-06
Reason
Freedom Broker
Price Target
$16
AI Analysis
2026-04-06
initiated
Buy
Reason
Freedom Broker initiated coverage of AngioDynamics with a Buy rating and $16 price target. The firm sees an improved growth profile for the company due to its pivot to \"higher-growth\" medical technology platforms.
Canaccord
Buy
downgrade
$18 -> $16
2026-04-06
Reason
Canaccord
Price Target
$18 -> $16
2026-04-06
downgrade
Buy
Reason
Canaccord lowered the firm's price target on AngioDynamics to $16 from $18 and keeps a Buy rating on the shares. The firm said they delivered a good FQ3 with a revenue beat and increased guidance. However, they think the initial negative stock reaction may have come from optics of the company's adj. EBITDA guidance, which was set at $10M-$12M for FY26. They noted AngioDynamics raised its revenue, adjusted EBITDA, and adjusted EPS guidance ranges, while maintaining its gross margin guidance
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ANGO
Unlock Now

Valuation Metrics

The current forward P/E ratio for AngioDynamics Inc (ANGO.O) is 96.15, compared to its 5-year average forward P/E of -119.70. For a more detailed relative valuation and DCF analysis to assess AngioDynamics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-119.70
Current PE
96.15
Overvalued PE
242.76
Undervalued PE
-482.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.24
Current EV/EBITDA
-107.14
Overvalued EV/EBITDA
172.08
Undervalued EV/EBITDA
-198.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.70
Current PS
1.36
Overvalued PS
2.52
Undervalued PS
0.87

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

단기 데이트레이닝에서 변동성이 5%로 예상되는 오늘 주식을 추천해줘
Intellectia · 11 candidates
Price: >= $5.00Price Change Pct: $3.00 - $7.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
ARVN logo
ARVN
Arvinas Inc
724.68M
UNIT logo
UNIT
Uniti Group Inc (Delaware)
2.39B
CALM logo
CALM
Cal-Maine Foods Inc
3.95B
ANGO logo
ANGO
AngioDynamics Inc
492.14M
SMFG logo
SMFG
Sumitomo Mitsui Financial Group, Inc
132.71B
HOPE logo
HOPE
Hope Bancorp Inc
1.50B
what companies have e
Intellectia · 7 candidates
Ticker
Name
Market Cap$
top bottom
AYI logo
AYI
Acuity Inc
8.80B
LNN logo
LNN
Lindsay Corp
1.22B
ANGO logo
ANGO
AngioDynamics Inc
492.14M
AIRS logo
AIRS
AirSculpt Technologies Inc
192.59M
NAMM logo
NAMM
Namib Minerals
122.92M
CCG logo
CCG
Cheche Group Inc
73.19M
best swing trades at or near $10
Intellectia · 27 candidates
Price: $8.00 - $12.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $25.00One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ANGO logo
ANGO
AngioDynamics Inc
462.46M
HLX logo
HLX
Helix Energy Solutions Group Inc
1.31B
HTLD logo
HTLD
Heartland Express Inc
910.75M
VMD logo
VMD
Viemed Healthcare Inc
313.27M
LNKB logo
LNKB
LINKBANCORP Inc
346.49M
SENS logo
SENS
Senseonics Holdings Inc
333.41M

Whales Holding ANGO

P
Paradigm Capital Management, Inc.
Holding
ANGO
+28.75%
3M Return
S
Systematic Financial Management LP
Holding
ANGO
+13.91%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is AngioDynamics Inc (ANGO) stock price today?

The current price of ANGO is 10.72 USD — it has decreased -0.65

What is AngioDynamics Inc (ANGO)'s business?

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

What is the price predicton of ANGO Stock?

Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AngioDynamics Inc (ANGO)'s revenue for the last quarter?

AngioDynamics Inc revenue for the last quarter amounts to 78.42M USD, increased 8.91

What is AngioDynamics Inc (ANGO)'s earnings per share (EPS) for the last quarter?

AngioDynamics Inc. EPS for the last quarter amounts to -0.19 USD, increased 72.73

How many employees does AngioDynamics Inc (ANGO). have?

AngioDynamics Inc (ANGO) has 675 emplpoyees as of April 22 2026.

What is AngioDynamics Inc (ANGO) market cap?

Today ANGO has the market capitalization of 445.83M USD.